Latest studies
- RecruitingPHASE3
A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus
This study looks at new ways to treat type 2 diabetes by testing two medicines, Elecoglipron and Dapagliflozin, both on their own and together. Researchers want to see how well they work and if they are safe for adults with type 2 diabetes.
Type 2 Diabetes MellitusUkraine - RecruitingPHASE3
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin
This study is testing a new medicine, Elecoglipron, for adults with type 2 diabetes and kidney problems. It compares Elecoglipron to a dummy pill (placebo) to see if it's safe and effective when taken with other usual diabetes medicines, including dapagliflozin.
Type 2 Diabetes MellitusType 2 Diabetes With Chronic Kidney DiseaseUkraine - RecruitingPHASE3
A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2)
This study is looking into a new treatment called GB-0895 for teenagers and adults with severe asthma that isn't well-controlled by usual medicines. Participants will receive either GB-0895 or a dummy treatment over about a year to see if it improves their health.
Severe AsthmaUkraine - RecruitingPHASE3
A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)
This study is testing a new medicine, Molnupiravir, to see if it can stop people at high risk of severe COVID-19 from becoming very ill. It's for people who can't take other COVID-19 treatments. We want to find out if it works better than a dummy treatment.
Coronavirus Disease (COVID-19)Ukraine - RecruitingPHASE1
Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants
This study is testing a new medicine, surovatamig, for rheumatoid arthritis (RA) and lupus (SLE). We want to see if it's safe, how it works in the body, and what dose is best. It's an early-stage study in adults.
Rheumatoid ArthritisSystemic Lupus ErythematosusUkraine - Active not recruitingPHASE3
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
This study looks at a new drug, pembrolizumab, combined with standard chemotherapy after surgery for certain types of womb cancer (endometrial cancer). We want to see if this combination helps stop the cancer from coming back and helps people live longer compared to chemotherapy alone.
Endometrial NeoplasmsUkraine - Active not recruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis
This study is comparing two medicines, fenebrutinib and ocrelizumab, to see which is safer and better at slowing down primary progressive multiple sclerosis (PPMS). It's for adults with PPMS and aims to understand how these treatments affect the disease progression.
Multiple Sclerosis, Primary ProgressiveUkraine - RecruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
This study is testing a new medication called Tulisokibart for people with moderate to severe Crohn's disease. Researchers want to see if it's safe and effective in reducing symptoms and improving the gut lining. It involves different ways of giving the medicine compared to a dummy treatment.
Crohn's DiseaseUkraine - RecruitingPHASE3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
This study looks at the long-term safety and effectiveness of a cancer drug called pembrolizumab (and related treatments) for people with advanced cancers. It's for patients who are already receiving these treatments in other studies and want to continue.
Solid TumorsHematologic MalignanciesUkraine - RecruitingPHASE2, PHASE3
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
This study is testing a new medicine, zilovertamab vedotin (ZV), combined with standard treatments for a type of lymphoma called diffuse large B-cell lymphoma (DLBCL). It's for people whose lymphoma has come back or hasn't responded to previous treatments.
DLBCLDiffuse Large B-Cell LymphomaUkraine - Active not recruitingPHASE2, PHASE3
A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
This study investigates an injection called litifilimab for adults with active lupus that mainly affects the skin, known as cutaneous lupus erythematosus (CLE). Researchers want to see if it helps reduce skin symptoms and is safe, especially for those whose current treatments aren't working well.
Subacute Cutaneous Lupus ErythematosusChronic Cutaneous Lupus ErythematosusUkraine - RecruitingPHASE3
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
This study is looking into a new treatment called KarXT + KarX-EC for agitation (feeling restless or upset) in people with Alzheimer's disease. It wants to see if the treatment is safe and if it helps reduce agitation.
Alzheimer's DiseaseUkraine - RecruitingPHASE3
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
This study looks at a new medicine for agitation in people with Alzheimer's. It aims to see if an experimental drug, given as capsules, is safe and works well over a long time for those who've been in similar studies before.
Alzheimer DiseaseAgitationUkraine - Active not recruitingPHASE2, PHASE3
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
This study looks at a new medicine called guselkumab for adults with moderately to severely active Crohn's disease. Researchers want to see how well it works and if it's safe compared to other treatments or a dummy medicine.
Crohn's DiseaseUkraine - RecruitingPHASE3
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
This study looks at a new medicine called orforglipron for people with heart disease or kidney disease. We want to see if it can improve their heart health over about five years. Half the people will get the new medicine, and half will get a dummy medicine (placebo).
Atherosclerosis Cardiovascular DiseaseChronic Kidney DiseaseUkraine - Active not recruitingPHASE3
Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy
This study looks at new drug combinations for advanced liver cancer that hasn't been treated before. It compares cabozantinib with atezolizumab against a standard treatment, sorafenib, to see which works better and is safer.
Hepatocellular CarcinomaUkraine - Active not recruitingPHASE3
An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS
This study looks at a new drug, apalutamide, alongside standard radiation for high-risk prostate cancer. Researchers want to see if this combination improves how long patients live without the cancer spreading, compared to usual treatments.
Prostatic NeoplasmsUkraine - Active not recruitingPHASE2
A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer
This study looks at a new drug, AZD9833, for post-menopausal women with advanced breast cancer that's hormone-sensitive (ER-positive) and HER2-negative. It compares AZD9833, taken by mouth, with an existing injected drug, Fulvestrant, to see which is safer and more effective.
Advanced ER-Positive HER2-Negative Breast CancerUkraine - Active not recruitingPHASE3
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis
This study looks at how well a medicine called risankizumab works and how safe it is for people with ulcerative colitis. It's for those who have already shown improvement with this medicine in a previous study.
Ulcerative Colitis (UC)Ukraine - Active not recruitingPHASE3
An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis
This study is an extension for people in the UK with moderately to severely active ulcerative colitis who have already taken part in a specific etrasimod trial. It aims to gather more information on the long-term safety and effectiveness of etrasimod for this condition.
Ulcerative ColitisUkraine - Active not recruitingPHASE3
Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer
This study is for men with cancer who are already taking darolutamide in another Bayer study and are doing well. It lets them keep taking the same medicine at the same dose, continuing their treatment journey under medical supervision.
CancerUkraine - Active not recruitingPHASE3
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)
This study looks at a new, higher dose of ocrelizumab for people with primary progressive multiple sclerosis (PPMS). Researchers want to see if this dose is safe and works better than the current approved dose to slow down the disease.
Multiple SclerosisUkraine - Active not recruitingPHASE3
Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).
This study, called POSEIDON, is testing new drug combinations for people with a type of lung cancer called non-small cell lung cancer (NSCLC). It's comparing usual chemotherapy with combinations of two new drugs, durvalumab and tremelimumab, to see if they work better.
Non Small Cell Lung Cancer NSCLCUkraine - Active not recruitingPHASE3
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer
This study looks at a drug called abemaciclib, given with standard hormone therapy after surgery for a type of breast cancer. We want to see if it's safe and helps stop the cancer coming back in people with certain high-risk breast cancers.
Breast CancerUkraine - Active not recruitingPHASE3
Avelumab Program Rollover Study
This study is for people with solid tumours already receiving a cancer medicine called avelumab in another clinical trial. It aims to safely continue their treatment and closely watch for any side effects, ensuring they receive ongoing care.
Solid TumorsUkraine - RecruitingPHASE3
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
This study looks at the long-term safety of a new medicine, KarXT, for people with changes in their thoughts and feelings due to Alzheimer's disease. Participants have already taken part in similar studies and will continue to be monitored for about a year.
Psychosis Associated With Alzheimer's DiseaseUkraine - RecruitingPHASE3
A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)
This study investigates if a drug called baricitinib can protect the body's insulin-making cells in children and adults newly diagnosed with type 1 diabetes. It aims to see if preserving these cells helps manage the condition better.
Diabetes Mellitus, Type 1Ukraine - Active not recruitingPHASE3
Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)
This study looks at new treatments for muscle-invasive bladder cancer — that's bladder cancer that's grown into the muscle layer. It compares surgery alone with surgery plus new drug treatments for people who can't have or choose not to have standard chemotherapy.
Urinary Bladder Cancer, Muscle-invasiveUkraine - Active not recruitingPHASE3
Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC
This study looks at a new drug, selumetinib, combined with standard chemotherapy (docetaxel) for a specific type of advanced lung cancer. It aims to see if this combination works better than chemotherapy alone for patients whose cancer has the KRAS gene mutation.
Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IVUkraine - Active not recruitingPHASE3
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)
This study is testing a new combination treatment for bladder cancer that hasn't spread. It combines standard chemotherapy and radiotherapy with a new drug called pembrolizumab, which helps your immune system fight cancer. We want to see if this new combination works better.
Urinary Bladder NeoplasmsUkraine - Active not recruitingPHASE3
A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.
This study looks at a new drug, tafasitamab, alongside standard treatments for follicular lymphoma and marginal zone lymphoma that have come back or not responded well. It aims to see if adding this new drug works better than the usual treatment alone.
Follicular LymphomaMarginal Zone LymphomaUkraine - Active not recruitingPHASE3
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
This study looks at a new drug, pacritinib, for people with myelofibrosis and very low platelet counts. It compares pacritinib to other standard treatments decided by your doctor, to see if it can help improve symptoms.
Primary MyelofibrosisPost-polycythemia Vera MyelofibrosisPost-essential Thrombocythemia MyelofibrosisUkraine - Active not recruitingPHASE3
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
This study looks at whether a new medicine, retatrutide, can help adults with obesity who also have heart disease or kidney problems. It aims to see if the medicine can reduce serious heart issues or stop kidney problems from getting worse.
Atherosclerotic Cardiovascular Disease (ASCVD)Chronic Kidney Disease (CKD)Ukraine - Active not recruitingPHASE1, PHASE2
A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children
This study is testing a new cancer medicine called larotrectinib for children with certain types of tumours. It looks at how safe the drug is, how it works in the body, and how well it helps treat cancers that have a specific gene change (NTRK fusion).
Solid Tumors Harboring NTRK FusionUkraine - RecruitingPHASE3
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
This study looks at new treatments for heart failure and kidney problems. Researchers are testing two different doses of a new drug combination against an existing medication to see if they can improve heart health and reduce hospital stays.
Heart Failure and Impaired Kidney FunctionUkraine - Enrolling by invitationPHASE3
A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
This study looks at the long-term effects and safety of a drug called Ralinepag for people with a lung condition called pulmonary arterial hypertension (PAH). It's for those who have already tried Ralinepag in a previous study.
PAHPulmonary HypertensionPulmonary Arterial HypertensionHypertensionUkraine - RecruitingPHASE3
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
This study looks at new medicines, retatrutide and tirzepatide, for adults with a type of fatty liver disease called MASLD. It aims to see if these drugs can help prevent serious liver problems. Some participants will receive a dummy drug (placebo) to compare.
Metabolic Dysfunction-Associated Steatotic Liver DiseaseUkraine - Active not recruitingPHASE3
A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer
This study looks at new ways to treat advanced or returning womb cancer. It compares a drug called dostarlimab, with or without another drug called niraparib, alongside standard chemotherapy, against chemotherapy plus a dummy drug, to see if these new treatments work better and are safe.
NeoplasmsUkraine - Active not recruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis
This study is looking at a new treatment called Ocrelizumab for primary progressive multiple sclerosis (PPMS). It compares Ocrelizumab to a dummy drug (placebo) to see how safe and effective it is for adults, including those who have had PPMS for a while.
Multiple Sclerosis, Primary ProgressiveUkraine - Active not recruitingPHASE3
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis
This study looks at the long-term safety and effectiveness of a medicine called ocrelizumab for people with Multiple Sclerosis (MS). It's for people already taking part in other ocrelizumab studies, to see how the treatment works over a longer time.
Multiple SclerosisUkraine - Active not recruitingPHASE3
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer
This study is testing a new combination of medicines, niraparib and abiraterone, with prednisone, for men with advanced prostate cancer that has spread and is resistant to hormone therapy. It compares this new combination against the standard treatment of abiraterone and prednisone to see if it works better.
Castration-Resistant Prostatic CancerUkraine - Active not recruitingPHASE3
Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)
This study is looking at a new way to treat advanced head and neck cancer. It combines a drug called pembrolizumab with surgery and radiotherapy, aiming to improve how long people live without the cancer returning compared to standard treatment.
Head and Neck NeoplasmsUkraine - Active not recruitingPHASE3
A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.
This study compares two treatments, Venetoclax plus Dexamethasone, and Pomalidomide plus Dexamethasone, for people with a specific type of multiple myeloma (t(11;14)-positive) that has come back or not responded to previous treatments. It aims to see which treatment works best at preventing the disease from getting worse.
Multiple MyelomaUkraine - Active not recruitingPHASE3
Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus
This study is testing a new injection, anifrolumab, for adults aged 18-70 with moderate to severe lupus (SLE) in the UK. Researchers want to see if it's safe and helps improve symptoms when added to their usual lupus treatment. Half get the new drug, half get a dummy drug.
Systemic Lupus ErythematosusUkraine - RecruitingPHASE3
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
This study looks at new treatments, sacituzumab tirumotecan alone or with pembrolizumab, for triple-negative breast cancer. It compares their effectiveness with standard chemotherapy to see if they help people live longer or stop cancer growth.
Triple Negative Breast NeoplasmsUkraine - Active not recruitingPHASE3
Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)
This study is looking at two new drugs, durvalumab and tremelimumab, for advanced lung cancer. It compares them to standard chemotherapy. Researchers want to see if the new combination helps people live longer and is safe as a first treatment for this type of cancer.
Non Small Cell Lung Carcinoma NSCLCUkraine - Active not recruitingPHASE3
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
This study compares a new drug, Giredestrant, with standard hormone therapy for early breast cancer. It's for people with a specific type of breast cancer (ER-positive, HER2-negative) who have already had surgery.
Early Breast CancerUkraine - Active not recruitingPHASE3
Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis
This study looks at a new drug, navitoclax, combined with ruxolitinib, or navitoclax alone, for adults with myelofibrosis whose previous treatment didn't work. It compares these to standard care to see how they affect spleen size and safety.
Myelofibrosis (MF)Ukraine - RecruitingPHASE3
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
This study looks at how two medicines, Baxdrostat and dapagliflozin, might help people with heart failure. We're testing if this combination can reduce hospital stays for heart failure or prevent death from heart problems in people with type 2 diabetes and high blood pressure.
Heart FailureUkraine - RecruitingPHASE3
A Long-term Extension Study of PCI-32765 (Ibrutinib)
This study offers ongoing access to a drug called ibrutinib for people already using it for certain blood cancers and conditions, who are still benefiting. It also helps gather more long-term information on how safe and effective ibrutinib is.
Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaMantle Cell LymphomaFollicular LymphomaUkraine